1

Your cart is empty.



Celebrating 22 YEARS of Regulatory Excellence!
Go with the Most-Trusted Regulations & Guidelines Books on the Market.


Now Available! Revised APRIL 1, 2024 Books!      Also check out our NEW Book:  Good Clinical Practice Regulations in the US & the EU  (Book 1C)!

Book M2:  2024 Mini Pocket-Sized (3" x 5") Code of Federal Regulations on Good Clinical Practice, 21 CFR Parts 11, 50, 54, 56, 312 (Does not include Part 314 or any ICH Guidelines)

Book M2: 2024 Mini Pocket-Sized (3" x 5") Code of Federal Regulations on Good Clinical Practice, 21 CFR Parts 11, 50, 54, 56, 312 (Does not include Part 314 or any ICH Guidelines)

$ 12.95

Return to Previous Page

This spiral-bound, 3" x 5" book contains the key US regulations governing the conduct of clinical studies for FDA approval. It also includes a detailed subject index for quick and convenient access to information. NOTE: It does not contain 21 CFR Part 314 or any ICH guidelines or FDA guidance documents. Users requiring ICH guidelines and FDA guidance documents should browse through the other books listed under the heading, "Clinical Research and Good Clinical Practice" on this website.

Books are pocket-sized with a tiny coil binding for easy transportability. Sections have printed section dividers for easy navigation between topics.

Who Uses this Book and How?
• Clinical Research staff, as job aids
• Training departments, as training handouts
• Human Resources, as part of new-employee orientation
• Legal/Regulatory/QA staff, for company-wide distribution

What's the Price?
• 1-249 copies:  $12.95             • 250-499 copies:  $11.95
• 500-749 copies: $10.95          • 750+ copies:  $9.95

Custom Cover Prices*?
• 1-24 copies:  unavailable             • 25-100 copies:  $2.00/book
• 100-249 copies: $1.00/book        • 250+ copies:  No charge

* Based on quantities of a single book title

• CFR Title 21:  Food and Drugs  (Revised as of April 1, 2024)
       Parts  11    Electronic Records/Electronic Signatures
                 50    Protection of Human Subjects
                 54    Financial Disclosure
                 56    Institutional Review Boards
                 312  Investigational New Drug Application

Click here to see an enlarged pdf cover